Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 mai 2025 21h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation...
27 mai 2025 10h56 HE | Source: Research and Markets

Schizophrenia Drugs Market Research Report 2025-2035: Advances in Antipsychotic Drug Development, Increasing Prevalence, & Greater Awareness and Access to Mental Health Care Bolster Growth

Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been...
01 nov. 2024 15h00 HE | Source: Teva Pharmaceutical Industries Ltd

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery technology...
21 sept. 2024 04h15 HE | Source: Teva Pharmaceutical Industries Ltd

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
29 févr. 2024 11h01 HE | Source: Research and Markets

Schizophrenia Treatment Advances with Emerging Pipeline Insights Through 2024

Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Schizophrenia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. This report confers a rich, panoramic view of...
27 févr. 2024 11h06 HE | Source: Research and Markets

Anorexia Nervosa Treatment Advances with New 2024 Pipeline Landscape Report

Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Anorexia Nervosa - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A Comprehensive Overview of Emerging...
14 févr. 2024 10h19 HE | Source: Research and Markets

Olanzapine Market Report 2024 - Global Trends, Forecasts and Competitive Analysis to 2030 - Opportunities in the Bipolar Disorder and Schizophrenia Markets

Dublin, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The "Olanzapine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...